期刊文献+

针对瘦素不同位点小干扰RNA对实验性肝纤维化的疗效

Efficacy of two siRNAs targeting against different sites of leptin gene on liver fibrosis
原文传递
导出
摘要 目的研究针对大鼠瘦素(Lep)基因两个不同位点的小干扰(siRNA)对肝纤维化的治疗效果。方法 40只雄性SD大鼠随机均分为4组:肝纤维化模型组(A组),给予60%CCl4(精致橄榄油配制)3ml/kg腹壁皮下注射,每周2次,共6周;siRNA1治疗组(B组),在模型制备2周后同时给予siRNA1质粒0.2mg/kg,每周2次,共6周;siRNA2治疗组(C组),在模型制备2周后同时给予siRNA2质粒0.2mg/kg,每周2次,共6周,siRNA质粒给予前与Lipofectamin偶联后通过尾静脉注射导入体内;正常对照组(D组),用精制橄榄油溶液代替CCl4皮下注射,每周2次,共6周。设计针对LepmRNA基因90和144位点的siRNA,分别记为siRNA1、siRNA2,并构建其表达载体;用Lipofectamin方法通过尾静脉注射转染入CCl4诱导的肝纤维化大鼠体内;然后分别采用RT-PCR、免疫组化方法检测Lep与Ⅰ、Ⅲ型胶原在肝脏组织中的表达,比较不同siRNA对实验性肝纤维化的疗效。结果转染LepsiRNA后Lep和Ⅰ、Ⅲ型胶原蛋白的表达均减少,但B组疗效优于C组。结论针对Lep基因不同位点的siRNA对肝纤维化治疗效果不同。 Objective To study and compare the effects of two small interfering RNAs(siRNAs) targeting against different sites of leptin gene on liver fibrosis between.Methods The model of hepatic fibrosis in rats was made by injection of carbon tetrachloride(CCl4).Forty male SD rats were randomly divided into two treating groups of hepatic fibrosis model(group siRNA1 and group siRNA2),model control(group A),and normal control(group D) with 10 rats each.The different small interfering RNAs,targeting leptin gene 90 and 144 were designed with computer according to analysis of the secondary structure of leptin gene.Leptin and Ⅰ,Ⅲ collagen were detected by immunohistochemistry and RT-PCR,respectively.Results The levels of leptin andⅠ,Ⅲ collagen were significantly decreased in gorups of siRNA1 and siRNA2 ,which was more in group siRNA2 than that in group siRNA1.Conclusion The siRNA targeting against different sites of leptin gene has different therapeutic effects on hepatic fibrosis.
出处 《江苏医药》 CAS CSCD 北大核心 2010年第18期2192-2195,共4页 Jiangsu Medical Journal
基金 南通市社会发展基金项目(S2007039)
关键词 瘦素 肝纤维化 小干扰核糖核酸 Leptin Liver fibrosis Small interfering RNA
  • 相关文献

参考文献3

二级参考文献26

  • 1李光明,谢青,史毅,李定国,张明均,徐芹芳,姜山,周惠娟,金由辛.抗结缔组织生长因子小分子干扰RNA防治大鼠肝纤维化研究[J].中华消化杂志,2005,25(6):336-339. 被引量:13
  • 2薛秀兰,林菊生,宋宇虎,蔡晓坤,周鹤俊.靶向leptin基因的siRNA对大鼠肝星状细胞生物学特性的影响[J].华中科技大学学报(医学版),2006,35(3):331-335. 被引量:5
  • 3Bataller R,Brenner DA.Liver fibrosis.J Clin Invest,2005,115:209-218.
  • 4Parsons CJ,Takashima M,Rippe RA.Molecular mechanisms of hepatic fibrogenesis.J Gastroenterol Hepatol,2007,22 Suppl 1:S79-84.
  • 5Anania FA.Leptin,liver,and obese mice--fibrosis in the fat lane.Hepatology,2002,36:246-248.
  • 6Honda H,Ikejima K,Hirose M,et al.Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver.Hepatology,2002,36:12-21.
  • 7Li GQ,Gu HX,Li D,et al.Inhibition of Hepatitis B virus cccDNA replication by siRNA.Biochem Biophys Res Commun,2007,355:404-408.
  • 8Siomi MC.Short interfering RNA-mediated gene silencing;towards successful application in human patients.Adv Drug Deliv Rev,2009,61:668-671.
  • 9Friedman SL. Liver fibrosis- from bench to bedside. J Hepatol,2003, 38(suppl 1): S38-S53.
  • 10Grotendorst GR. Connective tissue growth factor: a mediator of TGF-bata action on fibroblasts. Cytokine Growth Factor Rev, 1997,8: 171-179.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部